The World Health Organization (WHO) has released its inaugural dedicated guidelines for managing type 1 diabetes in adults, emphasizing the critical need for affordable insulin and improved access to care. These comprehensive recommendations advocate for multiple daily insulin injections, with lower-cost human insulin identified as the preferred option.
Until now, WHO guidance on insulin use primarily focused on broader diabetes management, leaving specific aspects of adult type 1 diabetes care largely unaddressed. Clinicians often relied on national and professional society protocols, many developed in high-income settings. The new guidelines aim to fill these crucial gaps, particularly in regions with limited resources.
Accurate Diagnosis is Key
A significant concern highlighted by the WHO is the frequent misdiagnosis of adult type 1 diabetes as type 2, especially where diagnostic tests and specialist care are scarce. Delayed diagnosis can lead to patients missing out on appropriate insulin treatment, escalating the risk of severe complications like diabetic ketoacidosis.
To combat this, the WHO recommends considering tests for pancreatic islet autoantibodies and C-peptide when a diagnosis is uncertain. Early and accurate identification ensures patients receive the lifelong insulin therapy essential for managing type 1 diabetes effectively.
Intensified Insulin Therapy and Choice
The new guidelines recommend intensified insulin therapy, which involves three or more injections daily. Doses should be carefully adjusted based on blood glucose levels, food intake, and physical activity. Regarding insulin choice, both human insulin and insulin analogues can be used for mealtime and basal treatment.
However, human insulin is explicitly preferred due to its generally lower cost. While long-acting insulin analogues may be considered in specific circumstances, affordability remains a primary driver. The WHO also suggests the use of insulin pens over traditional syringes for delivery.
Dr. Anoop Misra, Chairman of Fortis C-DOC Hospital for Diabetes and Allied Sciences, welcomed the recommendations, stating, "Affordable human insulin should be considered wherever clinically appropriate. It is highly effective in controlling blood glucose and can deliver results comparable to more expensive insulin analogues for most patients."
Misra acknowledged that human insulin might carry a slightly higher risk of hypoglycemia (low blood sugar), particularly if meals are delayed or doses are not adjusted correctly. He stressed that this risk can be mitigated through patient education, dietary advice, precise dose adjustments, and regular glucose monitoring. He praised the WHO's pragmatic approach, especially for countries like India, where sustained access and affordability are major challenges.
Monitoring and Global Burden
For monitoring, the guidelines recommend HbA1c testing up to every three months, targeting 7% or lower for most adults. They also cover self-monitoring through finger-prick blood glucose testing and continuous glucose monitoring.
These recommendations come as India faces a substantial diabetes burden, with the International Diabetes Federation estimating 89.8 million adults living with diabetes in 2024. Approximately 9.4 lakh people in India live with type 1 diabetes across all age groups, underscoring the urgency of these guidelines. Globally, the WHO estimates 9.5 million people were living with type 1 diabetes in 2025, with over 500,000 new cases diagnosed that year.
The WHO's preference for lower-cost human insulin, coupled with its guidance on diagnosis and monitoring, offers a scalable framework for health systems with diverse resource levels. These guidelines are intended to inform policymakers on clinical protocols, procurement, and the supply of essential insulin and monitoring devices, aligning with the WHO's 2030 target for universal access to affordable insulin and blood glucose self-monitoring for all people with type 1 diabetes.
It is important to note that these guidelines apply to adults aged 18 and above and do not cover children, diabetes during pregnancy, or advanced interventions such as insulin pumps.